Profile

Dana C. Matthews, MD

Dana C. Matthews, MD

Hematology-Oncology

On staff since March 1988

Children's Title: Director, Clinical Hematology; Chair, Blood Usage Committee

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

"Every time I walk into a clinic room to meet a new patient, I enjoy getting to know the patient and the parents, perhaps hearing a new language and learning something about what their life is like. I try hard to understand what they know, what they do not know, how I can best explain the diagnosis, and how we can work together most effectively to make decisions about diagnosis and treatment. I am profoundly fortunate to work with colleagues who are smart, warm and witty people as well as great clinicians. They care about our patients and about their colleagues on our team. Working together is stimulating, fun and gratifying."

Dana C. Matthews, MD, is director of clinical hematology at Seattle Childrens Hospital and head of the Pediatric Hemophilia Program; she is associate professor at the University of Washington School of Medicine. Her research interests include risk-based optimization of the treatment of pediatric thrombosis, clinical outcomes in patients with hemophilia, and novel treatments for immune thrombocytopenic purpura (ITP).

Current and pending research includes involvement in an international project to characterize immune responses to factor VIII that result in inhibiting antibodies, a multicenter pediatric trial of a thrombopomimetic agent in ITP, and pilot pediatric studies of a novel oral anticoagulant. She is interested in improving the outcome for pediatric patients with thrombosis by developing a pediatric thrombosis registry and developing clinical trials for subgroups of patients with thrombosis. She is medical director of the Anticoagulation Service for Seattle Childrens Hospital, and chair of the Blood Usage Committee. National responsibilities include membership on the Certification and Continuing Education Committee and the Nominating Committee of the American Society of Pediatric Hematology/Oncology. She is a member of the Board of Directors of the American Board of Pediatrics, and is completing a term on the hematology-oncology subboard. She will be Medical Editor for that subboard beginning in 2011.

Recommendations

  • Jerra Tonasket, WA 08.01.13

    We are VERY impressed with this impressive doctor! She knows what she's doing and we are confident with her skills. Highly Recommended!!!

  • Rebecca Richland, WA 05.18.12

    Dr. Matthews was warm, friendly and so helpful when she examined our failure-to-thrive baby. It's wonderful when a doctor who really knows their stuff also knows how to care for people. Thank you, Dr. Matthews.

  • Maureen Bristow, VA 12.14.11

    Dr. Dana Matthews and her team are outstanding!!! We have been extremely confident in her ability to treat our son.

  • Lynn Seattle, WA 12.01.10

    Dana is an amazing doctor that really has a handle on dealing not only with the patient but also with the families. She treats both sides with respect and I HIGHLY recommend her.

Overview

Board Certification(s)

Pediatric Hematology-Oncology
Pediatrics

Medical/Professional School

University of Washington School of Medicine, Seattle

Clinical Interests

Anemia, hemostasis, thrombosis, and autoimmune cytopenias

Research Description

My research interests include risk-based optimization of the treatment of pediatric thrombosis, and clinical outcomes in patients with hemophilia. In particular, I am participating in projects including an effort to characterize immune responses to factor VIII that result in inhibiting antibodies that significantly complicate the management of hemophilia A, and a prospective study of the development of inhibitors in young patients with hemophilia.

Additionally, I am interested in improving the outcome for pediatric patients with thrombosis by developing clinical trials for subgroups of patients with thrombosis.

Research Focus Area

Blood Disorders

Awards and Honors

Award Name Award Description Awarded By Award Date
SEATTLE'S TOP DOCTOR - 2014 Seattle Metropolitan Magazine 2014
SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
Seattle's Top Doc Seattle Met Magazine 2013
Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
U.S. News Top Doctor U.S. News and World Report 2012
Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
"Guide to America's Top Pediatricians" Consumer's Research Council of America 2009
Scholar in Clinical Research Leukemia and Lymphoma Society 1999 - 2003
Trustee, then Medical Advisor Leukemia Society of America, Washington/Alaska Chapter 1995 - 2003
Trustee, then Medical Advisor Leukemia Society of America, Washington/Alaska Chapter 1995 - 2003
Special Fellow Leukemia Society of America 1992
Fellow, Leukemia Society of America 1987
Alpha Omega Alpha University of Washington, School of Medicine, Seattle, Washington 1981
Phi Beta Kappa University of Washington, Seattle, Washington 1977

Publications

  • Dana C. Matthews, MD
    Inherited disorders of platelet function
    Pediatr Clin N Am , 2013 : 601475
  • Dana C. Matthews, MD
    Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: a retrospective cohort study.
    American Society of Hematology Annual Meeting , 2012 Dec. 8 - 2012 Feb. 11
  • Dana C. Matthews, MD
    Sequence-modified factor VIII variants having reduced immunogenicity
    American Society of Hematology annual meeting , 2012 Dec. 8 - 2012 Feb. 11
  • Dana C. Matthews, MD
    T cells from mild and severe hemophilia A inhibitor subjects recognized the same HLA-restricted epitope in factor VIII
    National Hemophilia Foundation Annual Meeting , 2012 Nov. 8 - 2012 Jan. 10
  • Dana C. Matthews, MD
    Erythrocyte disorders in infancy
    Averys Diseases of the Newborn , 2012 : 91080-1107
  • Dana C. Matthews, MD
    Determination of anti-factor VIIII antibody titers, isotypes and Epitopes by SPR Analysis of Human Plasma.
    American Society of Hematology Annual Meeting , 2011 Dec. 9 - 2011 Feb. 13
  • Dana C. Matthews, MD
    Fanconi anemia-like presentation in an infant with constitutional deletion of 21q including the RUNX1 gene
    Am J Med Genet , 2011 : 155A(7)1673-9
  • Dana C. Matthews, MD
    Allogeneic hematopoietic cell transplantation after conditioning with 131Ianti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Blood , 2010 : 1145444-5453
  • Dana C. Matthews, MD
    Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia
    Cancer Res , 2009 : 69185-192
  • Dana C. Matthews, MD
    Inherited coagulopathic states as a risk factor for complications in pediatric spine patients.
    International Meeting on Advanced Spine Techniques , 2008 July 8 - 2008 July 11
  • Dana C. Matthews, MD
    Consultative Hematology
    American Society of Hematology Self-Assessment Program , 2007 : 3466-499
  • Dana C. Matthews, MD
    The Brighton Collaboration Thrombocytopenia Working Group. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Vaccine , 2007 : 255717-24
  • Dana C. Matthews, MD
    131I-Anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
    Blood , 2006 : 1072184-91
  • Dana C. Matthews, MD
    Inferior Vena Cava thrombosis causing acute cauda equina syndrome: A case report.
    J Neurosurgery , 2006 : 104(1 suppl)46-9
  • Dana C. Matthews, MD
    Biodistribution of yttrium-90 [90Y] labeled anti-CD45 antibody in a nonhuman primate model
    Clinical Cancer Research , 2005 : 11787-794
  • Dana C. Matthews, MD
    Monoclonal antibodies as anti-leukemia and anti-lymphoma drugs. In: Clinical Bone Marrow and Blood Stem Cell Transplantation
    Clinical Bone Marrow and Blood Stem Cell Transplantation , 2004 : 3705-1715
  • Dana C. Matthews, MD
    Radioimmunotherapy and hematopoietic cell transplantation. In: Thomas Hematopoietic Cell Transplantation
    Thomas Hematopoietic Cell Transplantation , 2004 : 3198-208
  • Dana C. Matthews, MD
    Prevention of sensitization to D+ RBCs using RBC exchange and IV Rh immune globulin.
    Transfusion , 2004 : 441720-23
  • Dana C. Matthews, MD
    Rituximab in the very young: benefits in AIHA, at what risk? Invited "Inside Blood" capsule summary
    Blood , 2003 : 1013761
  • Dana C. Matthews, MD
    Use of radiolabeled antibodies in the treatment of childhood acute leukemia.
    Pediatr Transplant , 2003 : 7(Suppl 3)89-94
  • Dana C. Matthews, MD
    Therapy of acute leukemia with monoclonal antibodies and immunoconjugates.
    Treatment of Acute Leukemia: New Directions for Clinical Research , 2003 : 485-493
  • Dana C. Matthews, MD
    A comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
    Blood , 2003 : 1012340-2348
  • Dana C. Matthews, MD
    High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: a multivariable cohort analysis
    Blood , 2003 : 1022351-7
  • Dana C. Matthews, MD
    Conditionally cleavable radioimmunoconjugates: A novel approach for the release of radioisotopes from radioimmunoconjugates
    Bioconjug Chem , 2003 : 14927-33
  • Dana C. Matthews, MD
    The use of radioimmunoconjugates in stem cell transplantation.
    Bone Marrow Transplantation , 2002 : 29807-816
  • Dana C. Matthews, MD
    Antibody-based therapy of human leukemia
    Curr Opin Hematol , 2002 : 9316-321
  • Dana C. Matthews, MD
    High dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
    Blood , 2002 : 993158-3162
  • Dana C. Matthews, MD
    Monoclonal antibodies in acute leukemia
    New Frontiers in Cancer Therapy: Monoclonal antibody therapy of hematologic malignancies , 2001 : 219-236
  • Dana C. Matthews, MD
    Antibody-Targeted Therapy Of AML: An Update. In: Autologous Marrow and Blood Transplantation: Proceedings of the Tenth International Symposium.
    Autologous Marrow and Blood Transplantation: Proceedings of the Tenth International Symposium , 2001 : 229-242
  • Dana C. Matthews, MD
    Immunosuppressive Effects of 131I-anti-CD45 Antibody in Unsensitized and Donor-Antigen Presensitized H2-Matched, Minor Antigen Mismatched Murine Transplant Models.
    Cancer Research , 2001 : 615126-5131
  • Dana C. Matthews, MD
    Current uses of monoclonal antibodies in the treatment of acute leukemia.
    Semin Oncol , 2000 : 27Semin Oncol
  • Dana C. Matthews, MD
    Radioimmunotherapy in relapsed acute myeloid leukemia. Biologic Therapy of Leukemia:
    Acute Leukemia , 2000 : 15-9
  • Dana C. Matthews, MD
    Novel preparative regimens I: Tagged antibodies
    Handbook of Bone Marrow Transplantation , 2000 : 65-94
  • Dana C. Matthews, MD
    A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B cell lymphomas.
    Blood , 2000 : 962934-2942
  • Dana C. Matthews, MD
    Monoclonal antibodies in the treatment of acute leukemia
    Haematologica , 1999 : 84(Suppl 1)
  • Dana C. Matthews, MD
    The use of monoclonal antibodies in the treatment of AML
    Hematology , 1999 : 1999138-142
  • Dana C. Matthews, MD
    The clinical impact of increased sensitivity PT and aPTT coagulation assays.
    Amer. J. Clin. Pathol , 1999 : 112225-32
  • Dana C. Matthews, MD
    Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
    Leukemia , 1998 : 12(Suppl 1)S22-S36
  • Dana C. Matthews, MD
    Follow-up of relapsed B-cell lymphoma patients treated with Iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
    J Clin Oncol , 1998 : 163270-3278
  • Dana C. Matthews, MD
    The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies
    Winter JN: Blood Stem Cell Transplantation , 1997 : 121-139
  • Dana C. Matthews, MD
    The role of radioimmunotherapy in bone marrow transplantation
    Curr Opin Hematl , 1996 : 3438--45
  • Dana C. Matthews, MD
    Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors
    Blood , 1996 : 8751-58
  • Dana C. Matthews, MD
    Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
    Cancer Res , 1996 : 562123-2129
  • Dana C. Matthews, MD
    Allogeneic marrow transplantation for myelodysplastic synodrome with advanced disease morphology: a Phase II study of busulfan, cyclophosphamide and total body irradiation and analysis of prognostic factors
    J Clin Oncol , 1996 : 14200-6
  • Dana C. Matthews, MD
    Bone marrow transplantation for sickle cell disease: a multicenter collaborative investigation.
    New Engl J Med , 1996 : 334369-76
  • Dana C. Matthews, MD
    Barriers to bone marrow transplantation for sickle cell anemia.
    Biology of Blood and Bone Marrow Transplant , 1996 : 2100-104
  • Dana C. Matthews, MD
    The application of radioimmunotherapy to marrow transplantation.
    Bone Marrow Transplantation , 1995 : 15(Supplement 1)S188-S192
  • Dana C. Matthews, MD
    Targeted therapy for hematologic malignancies: has its promise been realized?
    Curr Opin Hematol , 1995 : 2235-239
  • Dana C. Matthews, MD
    Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation
    Blood , 1995 : 851122-1131
  • Dana C. Matthews, MD
    Neurologic complications following allogeneic marrow transplantation for sickle cell anemia.
    Blood , 1995 : 85879-884
  • Dana C. Matthews, MD
    Unrelated donor marrow transplantation in children.
    Blood , 1995 : 863247-3256
  • Dana C. Matthews, MD
    Post therapy imaging in high dose I-131 radioimmunotherapy patients
    Med Phys , 1994 : 211157-1162
  • Dana C. Matthews, MD
    Bone marrow transplantation for hemoglobinopathy and sickle cell disease.
    Recent Advances in Hematology , 1993 : 7119-134
  • Dana C. Matthews, MD
    High dose radioimmunotherapy of lymphoma
    Cancer Treatment and Research , 1993 : 6813-22
  • Dana C. Matthews, MD
    Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support.
    NEJM , 1993 : 3291219-1224
  • Dana C. Matthews, MD
    Is there a better way to deliver total body irradiation?
    Bone Marrow Transplantation , 1992 : 10(Suppl 1)77-81
  • Dana C. Matthews, MD
    Monoclonal antibodies in the study and therapy of hematopoietic cancers.
    Current Opinion in Immunology , 1992 : 4641-646
  • Dana C. Matthews, MD
    Therapy of Hematologic Malignancies Using Radioimmunotherapy (RAIT)
    Cambridge Medical Reviews: Haematology-Oncology , 1992 : 15-27
  • Dana C. Matthews, MD
    Tumor localization of radiolabeled anti-myeloid antibodies in a human acute leukemia xenograft model
    Cancer Research , 1992 : 5289-94
  • Dana C. Matthews, MD
    Use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
    Transplantation , 1992 : 54829 - 833
  • Dana C. Matthews, MD
    Chronic graft-versus-host disease and the late complications of bone marrow transplantation.
    Seminars in Hematology , 1991 : 28250-259
  • Dana C. Matthews, MD
    Radiolabeled antibody therapy of human B cell lymphomas: Advances in Experimental Biology and Medicine.
    Immunobiology of Proteins and Peptides VI , 1991 : 91-96
  • Dana C. Matthews, MD
    Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
    Blood , 1991 : 781864-1874
  • Dana C. Matthews, MD
    Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
    Cancer Research , 1991 : 515921-5928
  • Dana C. Matthews, MD
    Radiolabeled anti-CD45 monoclonal antibodies target hematolymphoid tissue in murine and macaque models
    Antib. Immunoconjug. Radiopharm , 1991 : 4713-719
  • Dana C. Matthews, MD
    Treatment of leukemia and lymphoma using antibody labeled with high doses of 131I.
    Antib. Immunoconjug. Radiopharm , 1991 : 4771-776
  • Dana C. Matthews, MD
    Chronic graft-versus-host disease: recent advances in diagnosis and treatment
    Bone Marrow Transplantation: Current Controversies , 1989 : 91511-522,
  • Dana C. Matthews, MD
    Homing receptors and metastasis
    Advances in Cancer Research , 1988 : 51361-390
  • Dana C. Matthews, MD
    Chronic graft-versus-host disease: pathogenesis, diagnosis, treatment and prognostic factors.
    Recent Advances and Future Directions in Bone Marrow Transplantation. Experimental Hematology Today,Recent Advances and Future Directions in Bone Marrow Transplantation , 1987 : 150-157
  • Dana C. Matthews, MD
    none

Research Funding

Grant Title Grantor Amount Award Date
Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia National Institutes of Health Sept. 30, 2010